Startup Scout 22 Sep 2022 Cartography Biosciences unearths cancer immunotherapy targets …as partnered programs. Parker said that there are many potential partners out there developing donor cell immunotherapies, engineered antibody drugs and antibody-drug conjugates. “All of them need new targets,” he… September 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Araris Biotech closes $24M financing round for ADCs …the Araris team as board observers. Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the company’s… October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the… May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies …technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These promising… December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Legochem Bioscience signs agreement with Glycotope to develop cancer drug …GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of biopharmaceutical drugs designed as a… July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2019 Channeling the Power of AI into Personalizing Medicine …established biotech Cambridge Antibody Technology. “I wanted to make a difference to patients’ lives — this was something that really interested me about human biology. That’s why I did biochemistry… October 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 German Biotech Reels in €34M for its Cancer-Killing Technology Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development… November 21, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2022 Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials …its Covid-19 vaccine candidate in June 2021, the German mRNA specialist CureVac pivoted to another candidate. The second-generation mRNA vaccine is being developed in partnership with GSK and showed promise… February 15, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Apr 2024 Chicago biotech: Seven players advancing the industry …financing round, to advance its oncology therapeutic candidate and develop its nanotechnology platform further. This funding will support the progression of their first oncology candidate, the selection of a second… April 2, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of… December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease …with high triglycerides and higher cardiovascular risk. Staten’s lead candidate, licensed from Belgian biotech argenx, is a human antibody that targets ApoC3, reducing fatty molecules in the blood. Though the… December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jul 2024 From data to discovery: Five bioinformatics companies you should know in 2024 …neuron disease that affects the nerve cells in the spinal cord and brain. The drug candidate VRG50635 is a small molecule PIKfyve inhibitor that was entirely discovered and developed using… July 11, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email